How Well Do Allergy Shots Work? Success Rates, Scores and QoL Data

A standardized mean difference (SMD) of -0.73 is a statistical way of expressing that, on average, allergy shot patients score 0.73 standard deviations lower on symptom measures than placebo patients. To translate this into clinical terms: in a typical rhinitis symptom scale where the standard deviation is around 2 points, an SMD of 0.73 represents roughly 1.5 fewer symptom score points — the difference between symptoms that are constantly intrusive versus symptoms that are manageable and allow normal daily activities. In published comparisons, an SMD of 0.73 is categorized as a 'moderate to large' effect in medical research. It's larger than the effect of antidepressants on depression in many meta-analyses, and substantially larger than most pharmacotherapy options for allergic rhinitis.

The Matricardi et al. comparison (JACI, 2011) provides the most rigorous indirect comparison: allergy shots (SCIT) produce a relative clinical impact on nasal symptom scores of -34.7% versus placebo; intranasal mometasone -31.7%; desloratadine (antihistamine) -12.0%; montelukast (leukotriene antagonist) -6.3%. On immediate symptom reduction, allergy shots and nasal steroids are roughly comparable — both substantially outperform antihistamines and leukotriene antagonists. The decisive difference is long-term trajectory: antihistamines and steroids require daily use indefinitely, with no benefit after stopping. Allergy shots produce disease-modifying immunity persisting 3-12 years after a completed course. For patients asking 'how well do shots work versus pills,' the answer depends heavily on the time horizon considered.

The number needed to treat (NNT) for allergy shots is approximately 3 for asthma symptom benefit based on the Abramson Cochrane review (2010), and NNT=4 for medication reduction. NNT=3 means that for every 3 patients who receive allergy shots, roughly 2 achieve significant symptom benefit (1 does not). To put this in medical context: the NNT for statins in preventing cardiovascular events over 5 years is approximately 25-50, depending on the population. NTT for antihypertensives preventing stroke is approximately 20-40. An NNT of 3 is considered an excellent treatment effect size — placing allergy shots among the most effective treatments available in outpatient allergy medicine, not just compared to other allergy treatments but compared to commonly used medications across medical specialties.

The pooled medication reduction from allergy shots is SMD -0.57 based on the Calderon Cochrane meta-analysis (2007). In practical terms, this means patients on SCIT use significantly less rescue antihistamine and nasal corticosteroid than placebo-treated patients. The Walker et al. trial (JACI, 2001) of grass SCIT reported an 80% medication reduction in the active group. In real-world practice, many patients reduce or discontinue daily antihistamine use by year 2-3 of maintenance, and some discontinue nasal steroids entirely. Medication reduction is clinically important for multiple reasons: reduced drug costs over time, avoidance of chronic antihistamine side effects, and for patients using intranasal steroids long-term, reduction of potential local mucosal effects. The medication reduction benefit begins during active treatment and persists for years after completing a full course.

House dust mite SCIT has some of the strongest evidence of any allergen — the Calderon Cochrane review for perennial allergic rhinitis (2010, CD007163) found symptom SMD -0.95 and medication SMD -1.88, both statistically significant. These effect sizes are actually larger than the overall rhinitis meta-analysis, making HDM one of the better-responding allergen categories. Lee et al. (Allergy Asthma Immunol Res, 2018) followed 304 Korean adults receiving HDM SCIT and found 76.6% cumulative clinical remission at an average follow-up of 4.9 years. A 2021 network meta-analysis by Nelson found SCIT produced the largest symptom effect of any modality for HDM, statistically outperforming both SLIT drops and tablets, though the magnitude of difference was modest. Long-term real-world data showed 55% of patients asymptomatic at 10 years post-HDM SCIT.